Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Secures $35M Investment

NEW YORK (GenomeWeb) — Agendia said today that it has raised $35 million in a deal with healthcare investment firm Athyrium Capital Management.

As part of the deal, Athyrium will receive a non-executive director seat on Agendia's board.

Agendia said it plans to use the proceeds of the financing to accelerate its commercial expansion in the US and other markets, including boosting adoption of its MammaPrint BluePrint next-generation sequencing-based kit for breast cancer recurrence risk testing and molecular subtyping.

The kit, which received CE marking earlier this year, is an RNA-sequencing based version of Agendia's existing MammaPrint and BluePrint tests, which are performed at the company's clinical laboratories in Irvine, California and Amsterdam.

Agendia said the financing will also support its investment in big data programs such as its ongoing full-genome profiling trials in the US and the Netherlands, as well as the establishment of new collaborative research programs for its precision oncology pipeline.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.